ADMA Biologics, Inc. vs BioCryst Pharmaceuticals, Inc.: Annual Revenue Growth Compared

Biotech Giants: ADMA vs. BioCryst Revenue Growth 2014-2023

__timestampADMA Biologics, Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 2014591554513608000
Thursday, January 1, 2015717763348257000
Friday, January 1, 20161066103726353000
Sunday, January 1, 20172276056025186000
Monday, January 1, 20181698529020653000
Tuesday, January 1, 20192934908348835000
Wednesday, January 1, 20204221978317812000
Friday, January 1, 202180942625157170000
Saturday, January 1, 2022154079692270827000
Sunday, January 1, 2023258214999331412000
Loading chart...

Unlocking the unknown

A Tale of Two Biotech Companies: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc. have showcased remarkable revenue growth over the past decade. Starting in 2014, ADMA Biologics reported a modest revenue of approximately $5.9 million, while BioCryst Pharmaceuticals began with $13.6 million. Fast forward to 2023, and ADMA's revenue has surged by over 4,200% to $258 million, while BioCryst's revenue has grown by more than 2,300% to $331 million.

This impressive growth trajectory highlights the resilience and innovation within the biotech sector. Notably, BioCryst experienced a significant leap in 2021, doubling its revenue from the previous year, while ADMA saw a consistent upward trend, particularly from 2020 onwards. These trends underscore the companies' strategic advancements and their ability to adapt in a rapidly evolving market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025